PFE earnings analysis
What we found in PFE's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Pfizer delivered 3% second-quarter revenue growth to $15.034 billion, supported by Eliquis, Padcev, Lorbrena and other non-COVID products, but GAAP diluted EPS fell to a $0.04 loss from $0.51 due largely to $4.325 billion of impairments and other significant items. Implied gross margin declined to 72.8% from 74.2% a year earlier, while implied operating margin fell to 20.4% from 25.8%, reflecting higher cost of sales and R&D. First-half operating cash flow improved to $3.450 billion, and management expanded long-term cost-savings targets, though patent expiries, COVID declines, legal charges and restructuring execution remain material offsets.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue growth excluding COVID products
- Second-quarter revenue rose $381 million, or 3%, year over year to $15.034 billion; excluding Comirnaty and Paxlovid, revenue increased 5% operationally.
- Key growth brands expanded strongly
- Eliquis revenue increased 21% to $2.425 billion, while Padcev rose 23% to $667 million and Lorbrena grew 41% to $354 million.
- Adjusted earnings remained resilient
- Adjusted diluted EPS was $0.77, compared with $0.78 in the prior-year quarter, despite $4.325 billion of asset-impairment charges in GAAP results.
- Operating cash generation improved
- First-half operating cash flow rose to $3.450 billion from $1.753 billion in the prior-year period, an increase of $1.697 billion.
- Cost program expanded
- Pfizer targets total Realigning Our Cost Base Program net savings of approximately $6.7 billion through 2029, including $1.0 billion of newly announced anticipated savings.
- Manufacturing savings target increased
- The Manufacturing Optimization Program now targets approximately $3.0 billion of total savings through 2029, including $1.5 billion from its newly announced phase.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Impairments drove GAAP loss
- GAAP diluted EPS moved to a $0.04 loss from $0.51 earnings per share a year earlier, driven in part by $4.325 billion of intangible-asset impairment charges.
- COVID franchise remains a sharp drag
- COVID-product revenue continued to contract: Paxlovid revenue fell 95% to $21 million and Comirnaty revenue fell 32% to $261 million in the quarter.
- Patent-expiry pressure is increasing
- Management now expects approximately $1.1 billion of unfavorable 2026 revenue impact from patent-based or regulatory-exclusivity expiries, with the rate of revenue reduction expected to accelerate over coming years.
- Gross margin contracted
- Cost of sales increased 8% to $4.092 billion, raising cost of sales to 27.2% of revenue from 25.8% a year earlier and reducing gross margin by 140 basis points.
- Savings require substantial upfront costs
- New restructuring phases require approximately $2.0 billion of one-time cost-base-program expenses and approximately $4.0 billion of manufacturing-optimization costs through 2029.
- Tariff protection is time-limited
- Section 232 pharmaceutical tariffs became effective for Pfizer on July 31, 2026; Pfizer's applicable tariff rate is zero only until January 20, 2029 under its U.S. government agreements.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.04
- Gross margin
- 72.8%
- Operating margin
- 20.4%
- Segment
- Biopharma: $14.661 billion, up 2% year over year
- Segment
- Pfizer CentreOne (PC1): $373 million, up 7% year over year
What they said about what is next.
The 10-Q discusses financial guidance and forward-looking cost-savings targets but does not provide a quantitative revenue or adjusted-EPS guidance range in the filing text.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 5, 2026
- Pfizer reported a Q1 2026 revenue of $14.5 billion, a 5% increase year-over-year, falling short of estimated revenue of $13.8 billion. Earnings per share (EPS) came in at $0.47, missing expectations of $0.72 per share.…
- 10-Q · November 4, 2025
- Pfizer reported Q3 revenue of $16,654 million and diluted EPS of $0.62 for the quarter ended September 28, 2025. Revenue declined versus the prior-year quarter ($17,702 million) and income before taxes fell to $3,334…
- 10-Q · August 5, 2025
- Pfizer reported Q2 revenue of $14.653B, up from $13.283B a year ago (+$1.370B, +10.3%), and swung to operating profit before taxes of $3.044B from a loss of $103M in Q2 2024. Net income attributable to Pfizer common…
- 10-Q · May 5, 2025
- Pfizer reported Q1 revenues of $13,715 million, down $1,164 million from Q1 2024 ($14,879 million), and GAAP diluted EPS of $0.52 versus $0.55 a year ago. Gross margin remained strong at ~79.3% (revenues $13,715M less…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing PFE makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever